JP2011093891A5 - - Google Patents

Download PDF

Info

Publication number
JP2011093891A5
JP2011093891A5 JP2010219798A JP2010219798A JP2011093891A5 JP 2011093891 A5 JP2011093891 A5 JP 2011093891A5 JP 2010219798 A JP2010219798 A JP 2010219798A JP 2010219798 A JP2010219798 A JP 2010219798A JP 2011093891 A5 JP2011093891 A5 JP 2011093891A5
Authority
JP
Japan
Prior art keywords
composition
carboxyvinyl polymer
ophthalmic
ruberin
tetrahydrozoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010219798A
Other languages
Japanese (ja)
Other versions
JP2011093891A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2010219798A priority Critical patent/JP2011093891A/en
Priority claimed from JP2010219798A external-priority patent/JP2011093891A/en
Publication of JP2011093891A publication Critical patent/JP2011093891A/en
Publication of JP2011093891A5 publication Critical patent/JP2011093891A5/ja
Pending legal-status Critical Current

Links

Claims (6)

（Ａ）カルボキシビニルポリマー、及び
（Ｂ）ネオスチグミン、タウリン、テトラヒドロゾリン、パントテン酸類、ベルベリン、ピリドキシン、及びアスパラギン酸、並びにそれらの塩からなる群より選択される１種以上の化合物を含有する眼科用組成物。 (A) carboxyvinyl polymer, and (B) neostigmine, taurine, tetrahydrozoline, pantothenic acid, base Ruberin, pyridoxine, and aspartic acid, as well as ophthalmic containing one or more compounds selected from the group consisting of salts Composition. カルボキシビニルポリマーの含有量が、組成物の全体に対して、０．００１〜１０ｗ／ｖ％である請求項１に記載の組成物。 The composition according to claim 1, wherein the content of the carboxyvinyl polymer is 0.001 to 10 w / v% based on the entire composition. （Ｂ）記載の化合物の含有量が、組成物の全体に対して、０．０００１〜３ｗ／ｖ％である請求項１又は２に記載の組成物。 (B) Content of the compound of description is 0.0001-3 w / v% with respect to the whole composition, The composition of Claim 1 or 2. 粘度が１０〜１００００ｍＰａ・ｓである請求項１〜３のいずれか一項に記載の組成物。 Viscosity is 10-10000 mPa * s, The composition as described in any one of Claims 1-3. 透明容器に充填されている請求項１〜４のいずれか一項に記載の組成物。 The composition as described in any one of Claims 1-4 with which the transparent container is filled. （Ａ）カルボキシビニルポリマーを含有する眼科用組成物に、（Ｂ） ネオスチグミン、タウリン、テトラヒドロゾリン、パントテン酸類、ベルベリン、ピリドキシン、及びアスパラギン酸、並びにそれらの塩からなる群より選択される１種以上の化合物を添加する、眼科用組成物の粘度低下抑制方法。 (A) in the ophthalmic composition containing a carboxyvinyl polymer, (B) neostigmine, taurine, tetrahydrozoline, pantothenic acid, base Ruberin, pyridoxine, and aspartic acid, as well as one or more selected from the group consisting of salts A method for suppressing a decrease in the viscosity of an ophthalmic composition, comprising adding the compound .
JP2010219798A 2009-09-30 2010-09-29 Composition for ophthalmology Pending JP2011093891A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010219798A JP2011093891A (en) 2009-09-30 2010-09-29 Composition for ophthalmology

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009228119 2009-09-30
JP2010219798A JP2011093891A (en) 2009-09-30 2010-09-29 Composition for ophthalmology

Publications (2)

Publication Number Publication Date
JP2011093891A JP2011093891A (en) 2011-05-12
JP2011093891A5 true JP2011093891A5 (en) 2014-05-08

Family

ID=44111225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010219798A Pending JP2011093891A (en) 2009-09-30 2010-09-29 Composition for ophthalmology

Country Status (1)

Country Link
JP (1) JP2011093891A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6687781B1 (en) * 2019-03-08 2020-04-28 ロート製薬株式会社 Ophthalmic composition with suppressed irritation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
JP2003055201A (en) * 2001-08-13 2003-02-26 Lion Corp Solubilized composition containing vitamin a compounds and method for stabilizing vitamin a compounds
JP2003201241A (en) * 2001-10-22 2003-07-18 Rohto Pharmaceut Co Ltd Ophthalmic composition
JP2004123634A (en) * 2002-10-03 2004-04-22 Lion Corp Ophthalmic composition
JP2006104114A (en) * 2004-10-04 2006-04-20 Rohto Pharmaceut Co Ltd Mucous membrane application composition
JP4890829B2 (en) * 2005-09-30 2012-03-07 ロート製薬株式会社 Azulene-containing aqueous solution
JP2008209677A (en) * 2007-02-27 2008-09-11 Menicon Co Ltd Germicide deactivating liquid agent
JP5235358B2 (en) * 2007-08-24 2013-07-10 ロート製薬株式会社 Aqueous pharmaceutical composition containing levocabastine and lidocaine

Similar Documents

Publication Publication Date Title
AR079890A1 (en) STABILIZATION OF ZINC OXIDE FILMS IN ORAL COMPOSITIONS
ES2556585T3 (en) Compositions comprising salbutamol sulfate
CO6640311A2 (en) Compounds, thioacetate compositions and methods of use
EA201070477A1 (en) TRANS-CLOMIFEN FOR THE TREATMENT OF METABOLIC SYNDROME
MX342423B (en) 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients.
JP2013522425A5 (en)
RS53056B (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-metoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BR112014009087A2 (en) xylitol stabilized etanercept formulations
JP2016510019A5 (en)
CL2014001437A1 (en) Compounds derived from aryl dihydropyridinone and piperidinone as inhibitors of monoacrylic glycerol acyltransferase (mgat2); pharmaceutical composition and combination; and use in the treatment and prevention of diabetes, hyperglycemia, retinopathy, metabolic syndrome, among other diseases.
UA111717C2 (en) ORAL INTRODUCTION AND METHYLNALTREXON LIPOPHILIC SALTS
JP2013541600A5 (en)
MX365108B (en) Piperidine derivatives for gpr119 agonist.
JP2014520090A5 (en)
EA201390799A1 (en) TRIAZOLOPRYRIDINS
BRPI0917502A2 (en) pharmaceutical composition, and methods for using an organic acid or antioxidant, to prevent discoloration caused when tranemaxamic acid and ascorbic acid are incorporated into the same composition, and to produce a solid pharmaceutical preparation for oral administration.
EA201170512A1 (en) COMPOSITION FOR ORAL ADMINISTRATION
AR089269A1 (en) COMPOSITIONS FOR ORAL CARE
AR085616A1 (en) INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE
EA201492091A1 (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION CONTAINING TERBINAPHID AND UREA
EA201201109A1 (en) ELECTRIC WOOD IN THIN-CUT CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION CONTAINING
RS53826B1 (en) Composition comprising powdered eggshell membrane for use in treating diabetes mellitus
EA201391198A1 (en) UNMATCHABLE, INVOLVING, LEATHER-CONDITIONING COMPOSITION, WHICH HAS A DISPELLING OIL PHASE AND CONTAINS 12-HYDROXISTARINIC ACID
JP2013513607A5 (en)